Enlivex Therapeutics
Israel - Ness ZionaBiotechnology
Focus: Enlivex Therapeutics is an Israeli biotech company developing Allocetra, a novel immune system rebalancing therapeutic using semi-apoptotic cells for infectious diseases and oncology. The company is publicly traded with a focused pipeline of 8 clinical programs across multiple indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Enlivex Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Enlivex Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Allocetra-OTS
Organ Dysfunction Syndrome SepsisClinical Trials (1)
NCT03925857Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS
Phase 1Help build intelligence for Enlivex Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.